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Abstract
Introduction:  Chronic  rhinosinusitis  (CRS)  is  termed  difﬁcult-to-treat  when  patients  do  not
reach acceptable  level  of  control  despite  adequate  surgery,  intranasal  corticosteroid  treat-
ment and  up  to  2  short  courses  of  systemic  antibiotics  or  corticosteroids  in  the  preceding
year. Recently,  high-volume  corticosteroid  nasal  irrigations  have  been  recommended  for  CRS
treatment.
Objective:  To  assess  high-volume  budesonide  nasal  irrigations  for  difﬁcult-to-treat  CRS.
Methods:  Prospective  uncontrolled  intervention  trial.  Participants  were  assessed  before-  and
3 months  after  nasal  irrigation  with  1  mg  of  budesonide  in  500  mL  of  saline  solution  daily  for  2
days. Subjective  (satisfactory  clinical  improvement)  and  objective  (SNOT-22  questionnaire  and
Lund--Kennedy  endoscopic  scores)  assessments  were  performed.
Results:  Sixteen  patients  were  included,  and  13  (81.3%)  described  satisfactory  clinical  improve-
ment. SNOT-22  mean  scores  (50.2--29.6;  p  =  0.006)  and  Lund--Kennedy  mean  scores  (8.8--5.1;
p =  0.01)  improved  signiﬁcantly.  Individually,  75%  of  patients  improved  SNOT-22  scores,  and  75%
improved Lund--Kennedy  scores  after  high  volume  budesonide  nasal  irrigations.
Conclusion:  High-volume  corticosteroid  nasal  irrigations  are  a  good  option  in  difﬁcult-to-treat
CRS control  of  disease,  reaching  81.3%  success  control  and  signiﬁcant  improvement  of  SNOT-22
and Lund--Kennedy  scores.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license
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Terapia  tópica  de  irrigac¸ão nasal  de  alto  volume  com  soluc¸ão de  budesonida
em  rinossinusite  crônica  de  difícil  tratamento
Resumo
Introduc¸ão:  A  rinossinusite  crônica  (RSC)  de  difícil  tratamento  é  aquela  inadequadamente  con-
trolada com  cirurgia,  corticosteroides  tópicos  em  spray  e  até  dois  ciclos  de  medicac¸ão  sistêmica
em um  ano.  Atualmente,  tem  sido  preconizado  o  uso  de  irrigac¸ões  nasais  de  corticosteroides
em alto  volume  para  seu  tratamento.
Objetivo:  Avaliar  o  uso  da  terapia  tópica  de  irrigac¸ões  nasais  com  budesonida  em  alto  volume
nos pacientes  com  RSC  de  difícil  tratamento.
Método:  Estudo  prospectivo  de  intervenc¸ão  não  controlado  em  RSC  de  difícil  tratamento  com  3
meses de  terapia  tópica  de  irrigac¸ão  (1  mg  de  budesonida  diluído  em  500  mL  de  soro  ﬁsiológico
para ser  utilizado  em  dois  dias).  Realizada  avaliac¸ão  subjetiva  (melhora  clínica  satisfatória)  e
objetiva (questionário  SNOT-22  e  classiﬁcac¸ão  endoscópica  de  Lund-Kennedy).
Resultados:  Foram  incluídos  16  pacientes,  sendo  que  13  (81,3%)  consideraram  sua  melhora
clínica satisfatória.  Houve  melhora  signiﬁcante  das  médias  de  SNOT-22  (50,2  a  29,6;  p  =  0,006)
e de  Lund-Kennedy  (8,8  a  5,1;  p  =  0,01).  Individualmente,  75%  dos  pacientes  apresentaram
melhora do  SNOT-22  e  75%,  do  Lund-Kennedy.
Conclusão:  A  terapia  tópica  de  irrigac¸ão  de  alto  volume  de  corticosteroide  é  uma  boa  opc¸ão
no controle  clínico  dos  pacientes  com  rinossinusite  crônica  de  difícil  tratamento,  com  controle
adequado de  81,3%  destes  pacientes  e  melhora  signiﬁcante  do  SNOT-22  e  do  Lund-Kennedy.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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hronic  rhinosinusitis  (CRS)  is  deﬁned  as  a  chronic  inﬂam-
atory  process  of  nasal  mucosa  and  paranasal  sinuses,
asting  more  than  12  weeks,  without  complete  resolution
f  symptoms.1 There  is  a  growing  perception  that  CSR  is
ot  a  single  disease,  but  a  spectrum  of  different  diseases
ith  similar  clinical  presentations,  whose  common  patho-
hysiological  mechanism  is  a  chronic  inﬂammation.2 In  other
ords,  the  term  CSR  is  nothing  more  than  a  large  label  or
mbrella  that  hosts  a  number  of  different  diseases  featuring
ypically  nasal  obstruction,  rhinorrhea,  olfactory  changes
nd/or  facial  pain.
Although  not  a  life-threatening  entity,  CSR  can  be  con-
idered  potentially  serious,  taking  into  account  the  impact
roduced  in  quality  of  life  of  affected  patients,  measured
y  generic  quality  of  life  questionnaires,  such  as  SF-363
r  questionnaires  speciﬁc  to  the  disease,  such  as  Sino-
asal  Outcomes  Test  (SNOT)-22,4 even  after  treatment.5
his  great  impact  becomes  even  more  relevant  if  we  con-
ider  that  5.51%  of  the  population  over  12  years  in  São  Paulo
ity  meet  epidemiological  diagnostic  criteria  for  CRS,  which
orresponds  to  approximately  500,000  individuals  with  CRS.6
In  general,  CRS  is  initially  treated  medically,  followed  by
urgical  treatment  if  necessary,  and  supplemented  by  post-
perative  topical  treatment.  The  initial  medical  treatment
s  also  known  as  ‘‘maximal  clinical  treatment’’,  because  it
onsists  of  a  combination  of  different  classes  of  drugs  in
rder  to  optimize  therapy  and  to  avoid  surgery.  But  there  is
o  consensus  on  the  composition  and  duration  of  maximal
linical  treatment,7 with  highly  variable  success  rates.8,9 In
ddition,  the  optimized  and  prolonged  use  of  drugs  such  as
i
o
pral  antibiotics  and  corticosteroids  can  lead  to  signiﬁcant
dverse  effects;  thus,  there  is  an  effort  for  replacing  sys-
emic  therapy  by  topical  nasal  therapy  to  achieve  control
f  CRS.10 The  direct  administration  of  the  drug  to  inﬂamed
issue  allows  an  increased  local  concentration  with  less  sys-
emic  absorption,  enhancing  therapeutic  efﬁcacy.11 For  this
eason,  surgery  has  been  considered  an  essential  step  in
reating  CRS,  by  opening  spaces  and  allow  for  an  adequate
istribution  of  the  drug  through  nasal  cavities.10,12,13
The  objective  of  CRS  treatment  is  to  achieve  and  main-
ain  control  of  the  disease,  which  is  deﬁned  as  a  state  in
hich  patients  have  no  symptoms  (or  their  symptoms  do
ot  bother  them),  combined  with  nasal  endoscopy  showing
ealthy  or  almost  healthy  mucosa,  and  in  need  only  of  top-
cal  nasal  medication.1 Due  to  the  large  heterogeneity  of
RS,  there  exists  a  proﬁle  of  patients  who,  despite  clinical
nd  surgical  treatments,  continue  to  experience  exacer-
ation  of  symptoms  and  inadequate  clinical  control.  The
uropean  Position  Paper  on  Rhinosinusitis  and  Nasal  Polyps
EPOS)  2012  deﬁnes  difﬁcult-to-treat  rhinosinusitis  as  that
ntity  in  which  patients  do  not  show  an  appropriate  clinical
ontrol  level  despite  sinonasal  surgery,  intranasal  cortico-
teroids  and  up  to  two  cycles  of  antibiotics  or  systemic
orticosteroids  in  the  last  year.1
Recently  there  has  been  a  perception  that  sprays  and
erosols  are  not  able  to  reach  paranasal  sinuses,  and  that,
n  most  cases,  these  products  do  not  even  reach  the  middle
eatus  area.  If  that  is  so,  such  methods  should  be  disre-
arded  in  favor  of  high-volume  methods,14,15 with  a  daily
rrigation  of  at  least  200  mL.11 In  view  of  evidence  of  superi-
rity  of  high  volume/pressure  solutions  with  respect  to  sinus
enetration,  nasal  irrigation  with  corticosteroids  at  daily
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pHigh-volume  budesonide  irrigations  in  difﬁcult-to-treat  chro
doses  ranging  from  250  g  to  1  mg  of  budesonide  have  been
used,  with  encouraging  results.16 In  this  line,  subgroups  tra-
ditionally  more  difﬁcult  to  control  (e.g.,  CRS  with  polyps  and
increased  tissue  eosinophilia)  had  even  better  therapeutic
response  than  the  other  subgroups.10
Taking  into  account  the  promising  results  of  the  use
of  nasal  irrigation  with  corticosteroids,  especially  in  those
more  difﬁcult  cases,  the  aim  of  this  study  was  to  evaluate
the  use  of  topical  therapy  with  high-volume  nasal  irrigation
with  budesonide  solution  in  patients  with  difﬁcult-to-treat
chronic  rhinosinusitis.
Method
Study  population
The  study  included  sixteen  patients  diagnosed  with  CRS,
with  or  without  nasal  polyps  (CRSwNP  or  CRSw/oNP,  respec-
tively)  who  met  the  criteria  for  difﬁcult-to-treat  CRS,
i.e.  inadequate  clinical  control  after  endoscopic  sinonasal
surgery,  use  of  topical  nasal  corticosteroids  in  spray  and  with
up  to  two  cycles  of  oral  antibiotics  and/or  corticosteroids  in
the  last  year,  with  follow-up  in  a  rhinology  outpatient  clinic.
The  diagnosis  of  CRS  was  deﬁned  according  to  search
criteria  suggested  by  EPOS  2012.1
Patients  younger  than  18  years  or  who  did  not  wish  to  par-
ticipate  in  the  study  were  excluded.  The  study  was  approved
by  the  Ethics  Committee  of  the  Institution  under  number
940.101.
Study  design
This  is  a  prospective,  interventional,  uncontrolled  study  in
patients  with  difﬁcult-to-control  CRS.  The  study  interven-
tion  was  the  high-volume  topical  therapy  by  nasal  irrigation
with  budesonide  solution.
Budesonide  was  prepared  by  a  manipulation  pharmacy
(VIP  Parma,  São  Paulo,  Brazil)  as  follows:  200  mL  of  max-
imally  ground  budesonide  in  a  mortar,  to  which  1  mL  of
glycerin  was  added  in  order  to  completely  dissolve  the
product.  After  checking  the  solubility,  this  product  was
transferred  to  a  cup  and  supplemented  with  glycerol  to  make
up  20  mL,  resulting  in  a  glycerol  solution  of  1%  budesonide.
Therefore,  each  1  mL  contained  10  mg  of  budesonide;  or
each  2  drops  contained  1  mg  of  the  drug.
Patients  were  instructed  to  dilute  2  drops  of  glycerin  solu-
tion  of  budesonide  1%  (corresponding  to  1  mg  of  budesonide)
in  500  mL  of  saline  solution.  Patients  were  also  instructed  to
divide  this  500  mL  volume  in  half,  i.e.  instilling  250  mL  each
day  for  two  days,  irrigating  his/her  nostrils  with  a  20-mL
syringe  in  pulses  or  jets,  and  to  continue  this  regimen  for
3  months.  No  previous  recommendation  was  proposed  as  to
frequency  of  irrigations;  the  patient  should  only  apply  the
amount  of  250  mL  on  a  daily  basis  (corresponding  to  the  use
of  500  g/day  of  budesonide).
Patients  were  evaluated  before  and  after  3  months  of
topical  irrigation  therapy.  The  following  epidemiological
characteristics  were  evaluated:  gender,  age,  type  of  CSR,
presence  of  comorbidity  and  number  of  previous  sinonasal
surgeries.  Moreover,  the  prescription  and  use  of  antibiotics
and/or  systemic  corticosteroids,  or  of  other  medications
w
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hat  might  interfere  with  the  treatment  of  CRS  during  topical
herapy  by  irrigation,  was  documented.
The  subjective  outcomes  evaluated  were  subjective
mprovement  and  degree  of  satisfaction  post-topical  ther-
py  by  irrigation.  When  the  topical  therapy  by  irrigation
ame  at  an  end,  patients  were  asked  if  there  was  improve-
ent  of  their  clinical  condition  (total  improvement,  partial
mprovement,  no  improvement,  worsening),  and  whether
hey  were  satisﬁed  with  the  degree  of  this  subjective
mprovement  (satisﬁed  or  dissatisﬁed).  ‘‘Therapeutic  suc-
ess’’  was  deﬁned  as  a  satisfactory  subjective  improvement
resented  by  the  patient.
Objective  outcomes  evaluated  were  scores  of  the
NOT-22  questionnaire  in  Portuguese4 and  endoscopic
lassiﬁcation  of  Lund--Kennedy.17 These  outcomes  were
uantitatively  and  qualitatively  evaluated.  Quantitative
valuation  of  objective  outcomes  involved  statistical  cal-
ulations  comparing  pre-  and  post-topical  therapy  by
rrigation.  For  the  qualitative  evaluation,  the  following
arameters  were  used:  the  minimally  important  difference
f  SNOT-22  =  14  points4; therefore,  differences  in  post-
re  scores  between  −7 and  +7  were  considered  as  ‘‘no
mprovement’’.  When  pre-post  difference  scores  reached
alues  <  −7,  they  were  considered  as  ‘‘improvement’’.  In
he  other  hand,  pre-post  differences  >  7  were  considered  as
‘worsening.’’
Absolute  scores  of  SNOT-22  (Portuguese  version)  between
 and  8 are  considered  normal18;  thus,  when  the  patient
howed  a  difference  value  <  −7  and  scores  for  post-topical
herapy  by  irrigation  ≤  8,  were  considered  as  ‘‘complete
mprovement’’.  As  to  Lund--Kennedy  scores,  post-pre  dif-
erences  =  zero  were  considered  as  ‘‘no  improvement’’,  any
egative  value  in  the  post-pre  difference  was  regarded
s  ‘‘improvement’’  and  any  positive  value  of  the  differ-
nce  as  ‘‘worsening’’.  A  post-topical  therapy  Lund--Kennedy
core  =  zero  was  considered  ‘‘complete  improvement’’.
Epidemiological  characteristics  and  outcomes  were  com-
ared  among  patients  with  and  without  satisfactory
mprovement.  Quantitative  variables  were  compared  by
tudent’s  t  test  or  Mann--Whitney  U  test,  depending  on
he  homogeneity  and  normality  of  samples;  and  qualitative
ariables  were  evaluated  by  Fisher’s  chi-squared  or  Fisher’s
xact  test.  For  all  statistical  tests,  p-values  <  0.05  were  con-
idered  as  signiﬁcant.
esults
he  characteristics  of  16  patients  with  difﬁcult-to  treat  CRS
ncluded  in  this  study  are  detailed  in  Table  1. The  epidemio-
ogical  characteristics  of  the  study  population  are  presented
n  Table  2.
Patient  #6  (a  woman)  used  30  mg  of  prednisone  con-
inuously  due  to  a  diagnosis  of  Churg--Strauss.  Patient  #10
a  male  renal  transplant  patient)  used  5  mg  of  prednisone
ontinuously  (in  addition  to  immunosuppressive  agents
s  sirolimus,  mycophenolate  sodium  and  tacrolimus),  and
atient  #12  (a  woman)  used  omalizumab  600  mg  every  2
eeks  due  to  severe  asthma.  In  face  of  the  severity  of
omorbidities,  the  drugs  used  by  these  patients  were  not  dis-
ontinued  during  the  period  of  topical  therapy  by  irrigation.
he  doses  of  the  drugs  mentioned  did  not  change  during  the
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tudy,  and  were  similar  to  the  doses  used  in  the  six  months
rior  to  the  study.
After  topical  therapy  by  irrigation,  we  asked  questions
n  subjective  outcomes  to  all  16  patients  (detailed  in  Table
).  Of  these,  6  reported  overall  subjective  improvement;
 informed  partial  subjective  improvement;  and  only  one
atient  felt  no  improvement,  totaling  15  patients  (93.8%)
ith  clinical  subjective  improvement.  In  addition  to  the
atient  without  improvement,  two  patients  with  partial
ubjective  improvement  were  not  satisﬁed  with  the  out-
ome  of  their  topical  therapy  by  irrigation,  totaling  13
atients  (81.3%)  with  satisfactory  subjective  improvement.
ll  patients  who  did  not  exhibit  satisfactory  subjective
mprovement  received  an  indication  for  a  new  surgical  pro-
edure,  with  orientation  to  restart  their  topical  therapy  by
rrigation  postoperatively.
Quantitative  evaluation  of  objective  outcomes  is  pre-
ented  in  Table  3. Globally,  our  quantitative  evaluation
howed  signiﬁcant  improvement  in  SNOT-22  (mean  of  50.2  in
re  to  29.6  in  post;  p  =  0.006)  and  in  Lund--Kennedy  (mean
f  8.8  in  pre-  to  5.1  in  post-;  p  =  0.01)  scores  in  our  study
opulation.  Corroborating  subjective  data,  patients  without
atisfactory  subjective  improvement  showed  no  signiﬁcant
mprovement  in  SNOT-22  and  Lund--Kennedy  scores,  unlike
he  rest  of  our  study  population.
Qualitative  evaluation  of  objective  outcomes  is  demon-
trated  in  Table  4; this  assessment  showed  that  no  patient
xhibited  poorer  SNOT-22  scores,  4  (25%)  showed  no
mprovement,  and  12  (75%)  improved.  Of  the  twelve  patients
ith  improvement,  one  of  them  was  considered  as  achiev-
ng  total  improvement  (6.3%).  As  to  Lund--Kennedy  scores,
o  patient  suffered  worsening,  4  (25%)  showed  no  improve-
ent,  and  12  (75%)  improved.  Of  these  12  patients,  5  (31.3%)
chieved  full  recovery  in  their  endoscopic  score.
There  were  no  predictive  factors  of  subjective  ther-
peutic  success  in  our  study  sample.  However,  patients
ith  satisfactory  subjective  improvement  had  signiﬁ-
antly  greater  reduction  and  lower  ﬁnal  values  for  their
und--Kennedy  score  (Table  3).
iscussion
n  the  evaluation  of  difﬁcult-to-treat  patients,  that  is,  those
ho  had  already  undergone  endoscopic  sinonasal  surgery
ithout  adequate  clinical  control  with  topical  nasal  corti-
osteroids  in  the  form  of  spray  and  up  to  two  cycles  of  oral
ntibiotics  and/or  corticosteroids  in  the  preceding  year,  the
resent  study  demonstrated  efﬁcacy  of  high-volume  nasal
rrigation  with  a  solution  of  budesonide,  with  81.3%  of  suc-
ess  in  clinical  management.  Although  this  design  does  not
llow  for  a  high-level  of  evidence,  we  must  consider  that
he  study  achieved  a  high  success  rate  in  patients  who
ad  previously  failed  treatment  with  topical  nasal  cortico-
teroids  in  the  form  of  spray.  Considering  only  objective
riteria,  topical  therapy  by  irrigation  was  able  to  signiﬁ-
antly  reduce  SNOT-22  and  Lund--Kennedy  scores,  resulting
n  75%  improvement  in  objective  parameters.Unfortunately,  there  is  little  evidence  in  the  literature
egarding  the  use  of  nasal  irrigation  with  corticosteroids,
ecause  this  is  a non-standardized  therapeutic  modal-
ty  (off-label).  The  early  studies  involved  low-volume
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Table  2  Epidemiological  characteristics  and  subjective  outcomes.
Data  Groups
With
satisfactory
improvement
Without
satisfactory
improvement
Total  Test  p-value
Patients,  total n  (%)  13  (81.3)  3  (18.7)  16  (100)
Female gender n  (%) 10  (76.9) 2  (66.6) 12  (75)  Fisher  1
Age (years) Mean  (SD) 48.9  (10.2) 59.3  (6.4) 50.9  (10.3) T  0.11
Nasosinusal polyposis n  (%) 9  (69.2) 2  (66.6) 11  (68.8) Fisher  1
Asthma n  (%)  6  (46.2)  1  (33.3)  7  (53.8)  Fisher  1
ASA intolerance  n  (%)  2  (15.4)  0  (0.0)  2  (12.5)  Fisher  1
Rhinitis n  (%)  3  (18.8)  0  (0.0)  3  (18.8)  Fisher  1
Previous surgeries  Mean  (SD)  1.5  (0.6)  2.7  (2.1)  1.8  (1.1)  T  0.09
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sn, number; %, percentage; SD, standard deviation; ASA, acetylsal
irrigation19--21;  however,  low-volume  irrigation  methods  can-
not  reach  paranasal  sinuses,12 and  are  clearly  inferior  to
high-volume  irrigation,15 as  demonstrated  in  the  present
study.  The  only  well-designed  study  (a  randomized  con-
trolled  clinical  trial  --  level  1b)  using  high-volume  irrigation
showed  no  difference  among  groups  of  irrigation  with  saline,
nasal  irrigation  by  spray  with  budesonide,  and  high-volume
irrigation  with  budesonide  in  patients  with  Samter’s  triad
soon  after  endoscopic  sinonasal  surgery.22 However,  in  this
study  patients  who  required  systemic  corticosteroids  in  the
post-operative  period  were  excluded,  and  this  may  have
selected  a  more  neutrophilic  phenotype,  which  would  not
beneﬁt  so  much  with  nasal  irrigation  with  corticosteroids.10
The  ﬁrst  pilot  study  with  high-volume  irrigation  with
budesonide  only  was  published  in  2009  by  Steinke  et  al.,  and
reported  that  6  (75%)  of  eight  patients  studied  showed  signif-
icant  improvement  of  sinonasal  symptoms  in  a  visual  analog
scale  and  in  Lund--MacKay  scores.16 Another  retrospective
study  conducted  by  Jang  et  al.  compared  patients  in  periods
when  they  used  versus  did  not  use  high-volume  irrigation
with  budesonide  after  endoscopic  sinonasal  surgery;  the
r
e
S
Table  3  Quantitative  assessment  of  objective  outcomes.
Data  
With
satisfactory
improvement
Patients,  total  n  (%)  13  (81.3)  
SNOT-22 pre Mean  (SD)  47.7  (19.6)  
SNOT-22 post  Mean  (SD)  25.3  (19.3)  
Difference SNOT-22 Mean  (SD)  22.4  (23.4)  
Pre vs.  post  t  test  p-value 0.007a
Lund--Kennedy  pre  Mean  (SD)  8.5  (3.5)  
Lund--Kennedy  post  Mean  (SD)  4.2  (4.3)  
Difference  Lund--Kennedy  Mean  (SD)  4.3  (4.0)  
Pre  vs.  post  t  test  p-value  0.009a
N, number; %, percentage; SD, standard deviation.
a Statistical signiﬁcance. acid.
tudy  showed  that  55%  of  60  patients  had  lower  SNOT-20
cores,  and  56%  of  60  patients  had  lower  Lund--Kennedy
cores  while  using  topical  therapy  by  irrigation.  The  SNOT-
0  scores  measured  during  topical  therapy  by  irrigation  were
igniﬁcantly  lower  than  without  topical  therapy.  This  was  not
he  case  with  Lund--Kennedy  scores.23 The  largest  study  was
onducted  by  Snidvongs  et  al.;  these  authors  prospectively
ecruited  111  patients,  also  soon  after  their  endoscopic  sinus
urgery,  and  introduced  high-volume  irrigation  as  topical
herapy  with  signiﬁcant  improvement  in  Likert  symptoms’
core  and  in  SNOT-22  and  endoscopic  scores.  Moreover,
n  adequate  control  in  94.6%  of  patients  was  obtained
fter  three  months,  with  six  patients  (5.4%)  requiring  oral
orticosteroids,  and  only  four  requiring  a new  surgical  treat-
ent  subsequently.10 Our  study  showed  75%  of  patients  with
mprovement  of  SNOT-22  scores,  similar  to  the  study  of
teinke  et  al.16 and  with  more  success  than  Jang  et  al.
tudy23; this  also  occurred  with  respect  to  improvement
ates  of  Lund--Kennedy  scores  (75%  vs.  56%).  SNOT-22  scores
xhibited  a  signiﬁcant  reduction  in  this  study,  as  well  as  in
nidvongs  et  al.10 and  Jang  et  al.23 studies.  Lund--Kennedy
Groups
Without
satisfactory
improvement
Total  t  test  p-value
With  vs.  without
improvement
3  (18.7)  16  (100)
61.0  (16.4)  50.2  (19.3)  0.31
48.0  (16.5)  29.6  (20.4)  0.13
13.0  (4.4)  20.6  (21.6)  0.19
0.39  0.006a
10.3  (1.5)  8.8  (3.3)  0.19
9.3  (1.2)  5.1  (4.4)  0.002a
1.0  (1.0)  3.7  (3.8)  0.02a
0.42  0.01a
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cores  also  fell  signiﬁcantly  in  this  study,  similar  to  Snid-
ongs  et  al.10 study,  but  this  was  not  evident  in  the  study
y  Jang  et  al.23 The  clinical  control  rate  in  this  study  was
1.3%,  a  ﬁgure  lower  than  the  percentage  of  94.6%  obtained
y  Snidvongs  et  al.10
It  is  noteworthy  that  the  variability  of  results  among
tudies  could  be  due  to  the  heterogeneity  of  the  patients
ncluded.  The  proﬁle  of  patients  recruited  in  our  study  was
hat  of  difﬁcult-to-control  CRS,  which,  in  theory,  would
ncompass  a  worse  prognostic  group,  in  comparison  with
hose  in  the  other  studies.  Moreover,  despite  the  fact  that
ll  patients  in  this  study  had  been  previously  operated,
he  topical  therapy  by  irrigation  was  not  started  in  the
mmediate  post-operative  period,  as  it  was  in  the  study  of
nidvongs  et  al.10 This  lengthy  interval  between  surgery  and
he  onset  of  nasal  irrigation  therapy  could  allow  a  worse
ndoscopic  appearance  to  develop,  including  blockage  of
inuses  by  inﬂammatory  tissue,  which  would  not  allow  for  a
roper  penetration  of  topical  therapy  by  irrigation  into  nasal
inuses,24 and  contribute  to  the  lower  success  rate  in  this
tudy.  Furthermore,  in  the  study  of  Snidvongs  et  al.,  with
arly  postoperative  patients,  there  is  no  way  to  dissociate
uccess  rates  of  topical  therapy  versus  surgery  itself.10
The  corticosteroid  dose  is  another  variable  that  should
e  considered:  the  studies  cited  used  1  mg/day  of  budes-
nide  or  betamethasone,  while  in  the  present  study  our
atients  used  budesonide  500  g/day.  We  choose  a  lower
ose  because  this  is  closer  to  the  usual  dose  of  budes-
nide  nasal  spray  for  CRS,  which  is  400  g/day.  But  this
ption  may  have  also  contributed  to  a  lower  success  rate
f  this  study,  when  compared  to  that  of  Snidvongs  et  al.10
n  the  other  hand,  the  dose  we  chose  leads  to  another
onsideration:  all  patients  included  in  this  study  did  not
chieve  clinical  control  when  using  400  g/day  of  budes-
nide  nasal  spray;  however,  with  a small  increase  in  the
mount  of  corticosteroids  (500  g/day)  and  a  change  in  the
orm  of  administration  (high-volume  nasal  irrigation),  81.3%
f  these  patients  did  achieve  clinical  control.  This  ﬁnding
an  corroborate  the  concept  that  high-volume  nasal  irriga-
ions  with  budesonide  solution  not  only  have  the  advantage
f  a  drug  distribution  directly  to  paranasal  sinuses,  but  also
ring  the  beneﬁt  mechanical  washings  with  saline.24 Thanks
o  the  quality  and  quantity  of  aggregated  evidence,  irriga-
ions  with  saline  are  a  possible  recommendation  for  use  in
RS  patients,  while  high-volume  irrigation  as  topical  ther-
py  with  corticosteroids  is  still  considered  only  a  therapeutic
ption  for  CSR  patients.11
onclusion
igh-volume  irrigation  with  corticosteroids  as  topical  ther-
py  is  a good  option  in  the  management  of  patients  with
ifﬁcult-to  treat  chronic  rhinosinusitis,  signiﬁcantly  improv-
ng  their  objective  and  subjective  parameters.  Both  SNOT-22
nd  Lund--Kennedy  scores  improved  in  75%  of  cases,  with
atisfactory  subjective  control  in  81.3%  of  these  patients.onﬂicts of  interest
he  authors  declare  no  conﬂicts  of  interest.
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